Get the Stockscreener App
6.7548
1.65%
0.0948
Immuneering Corp stock is traded at $6.7548, with a volume of 766.21K.
It is up +1.65% in the last 24 hours and down -11.62% over the past month.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.
See More
Previous Close:
$6.66
Open:
$6.67
24h Volume:
766.21K
Relative Volume:
0.49
Market Cap:
$436.49M
Revenue:
$317.00K
Net Income/Loss:
$-53.47M
P/E Ratio:
-3.574
EPS:
-1.89
Net Cash Flow:
$-49.31M
1W Performance:
+5.95%
1M Performance:
-11.62%
6M Performance:
+100.89%
1Y Performance:
+200.89%
1-Day Range:
$6.61
$6.98
1-Week Range:
$6.20
$6.98
52-Week Range:
$1.10
$10.08
Immuneering Corp Stock (IMRX) Company Profile
Name
Immuneering Corp
Sector
Industry
Phone
617-500-8080
Address
245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Compare IMRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
IMRX
Immuneering Corp
|
6.76 | 430.04M | 317.00K | -53.47M | -49.31M | -1.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
454.32 | 116.65B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
772.68 | 82.03B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.01 | 52.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
836.81 | 51.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
174.59 | 37.61B | 447.02M | -1.18B | -906.14M | -6.1812 |
Immuneering Corp Stock (IMRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-31-25 | Initiated | Leerink Partners | Outperform |
| Dec-13-24 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Mar-15-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-15-24 | Reiterated | Needham | Buy |
| Mar-15-24 | Downgrade | TD Cowen | Outperform → Market Perform |
| Dec-01-23 | Initiated | Needham | Buy |
| Jun-26-23 | Resumed | Oppenheimer | Outperform |
| Apr-19-23 | Upgrade | Mizuho | Neutral → Buy |
| Apr-19-23 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Mar-30-23 | Initiated | Mizuho | Neutral |
| Feb-03-23 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| Jul-08-22 | Initiated | Chardan Capital Markets | Buy |
| Apr-01-22 | Initiated | Oppenheimer | Outperform |
| Jan-07-22 | Initiated | Piper Sandler | Overweight |
View All
Immuneering Corp Stock (IMRX) Latest News
Institutional investors control 36% of Immuneering Corporation (NASDAQ:IMRX) and were rewarded last week after stock increased 19% - Sahm
Immuneering to announce OS data from Phase 2a trial of atebimetinib, mGnP - TipRanks
Immuneering to provide 12-month survival data for pancreatic cancer drug - Investing.com
Immuneering to provide 12-month survival data for pancreatic cancer drug By Investing.com - Investing.com South Africa
Immuneering to Announce 12-Month Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on January 7, 2026 - The Manila Times
Wall Street Zen Downgrades Immuneering (NASDAQ:IMRX) to Sell - MarketBeat
Can Immuneering Corporation stock outperform in 2025 bull marketWeekly Trend Report & Long-Term Growth Plans - Улправда
Immuneering on track to dose first patient in pancreatic cancer trial in 2026 - MSN
Is Immuneering Corporation stock attractive for income investorsJuly 2025 Update & Stepwise Trade Signal Guides - Улправда
Why Immuneering Corporation stock attracts global investorsGlobal Markets & Accurate Buy Signal Notifications - Улправда
Immuneering to begin Phase 3 trial of pancreatic cancer drug mid-2026 - Investing.com Australia
Immuneering To Initiate Phase 3 Atebimetinib Trial In Pancreatic Cancer In Mid-2026 - Nasdaq
Immuneering stock rises after FDA and EMA align on Phase 3 trial design By Investing.com - Investing.com South Africa
Immuneering stock rises after FDA and EMA align on Phase 3 trial design - Investing.com
Immuneering Advances Towards Dosing First Patient in Phase 3 Atebimetinib Trial for First-Line Metastatic Pancreatic Cancer Patients, Securing Alignment with FDA and EMA - The Manila Times
Global trial to test drug combo for first-line pancreatic cancer patients - Stock Titan
Immuneering to be added to the Nasdaq Biotechnology Index - TipRanks
Immuneering to be Added to the Nasdaq Biotechnology Index (NBI) - The Manila Times
Immuneering (Nasdaq: IMRX) to be added to Nasdaq Biotechnology Index on Dec. 22 - Stock Titan
Immuneering Corporation (NASDAQ:IMRX) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Pancreatic Cancer Survival Gains Accelerate as Novel Therapies Advance - Sahm
Top investors say Immuneering Corp (IMRX) ticks everything they need - setenews.com
You Should Read This Analysis Before Investing in Immuneering Corp (NASDAQ:IMRX) - uspostnews.com
This trade activity should not be overlooked: Immuneering Corp (IMRX) - setenews.com
Immuneering (IMRX) Stock Analysis Report | Financials & Insights - Benzinga
We Think Immuneering (NASDAQ:IMRX) Can Afford To Drive Business Growth - Yahoo Finance
Will Immuneering Corporation stock see insider buyingJuly 2025 Levels & Real-Time Stock Price Movement Reports - moha.gov.vn
Immuneering (IMRX) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Wall Street Analysts See a 126.21% Upside in Immuneering (IMRX): Can the Stock Really Move This High? - Yahoo Finance
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
Immuneering Corporation (IMRX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
A new trading data show Immuneering Corp (IMRX) is showing positive returns. - Setenews
Companies Like Immuneering (NASDAQ:IMRX) Are In A Position To Invest In Growth - simplywall.st
Combining machine learning predictions for Immuneering Corporation2025 Technical Overview & Technical Pattern Based Signals - newser.com
Best data tools to analyze Immuneering Corporation stockTrend Reversal & Stepwise Trade Execution Plans - newser.com
How Immuneering Corporation stock compares to growth peersLong Setup & Reliable Breakout Stock Forecasts - newser.com
Is Immuneering Corporation stock poised for growthBear Alert & Community Trade Idea Sharing - newser.com
Does Immuneering Corporation qualify in momentum factor screeningMarket Growth Review & Step-by-Step Trade Execution Guides - newser.com
Can Immuneering Corporation stock reach $100 price targetEntry Point & Long-Term Safe Investment Plans - newser.com
Will Immuneering Corporation stock beat EPS estimatesPortfolio Gains Report & High Win Rate Trade Alerts - newser.com
Can machine learning forecast Immuneering Corporation recoveryMarket Volume Report & Entry Point Confirmation Signals - newser.com
Immuneering Corporation (NASDAQ:IMRX) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Is Immuneering Corporation stock undervalued vs historical averages2025 Valuation Update & Real-Time Stock Movement Alerts - newser.com
What data driven models say about Immuneering Corporation’s futureMarket Activity Summary & Safe Entry Point Alerts - newser.com
Why Immuneering Corporation stock is recommended by analystsWeekly Market Outlook & Fast Exit and Entry Trade Guides - newser.com
Can momentum traders help lift Immuneering CorporationJuly 2025 Analyst Calls & Advanced Technical Analysis Signals - newser.com
Immuneering Corp Stock (IMRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Immuneering Corp Stock (IMRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Morales Mallory | Chief Accounting Officer |
Oct 01 '25 |
Buy |
6.39 |
300 |
1,917 |
27,533 |
| Neufeld Leah R | CHIEF PEOPLE OFFICER |
Oct 01 '25 |
Buy |
6.38 |
800 |
5,103 |
23,344 |
| Bookman Michael | CHIEF LEGAL OFFICER, SECRETARY |
Oct 01 '25 |
Buy |
6.83 |
1,020 |
6,966 |
4,870 |
| Feinberg Peter | Director |
Sep 30 '25 |
Buy |
7.03 |
7,500 |
52,730 |
149,266 |
| Feinberg Peter | Director |
Sep 29 '25 |
Buy |
7.18 |
5,000 |
35,900 |
141,766 |
0.08%
3.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):